January 16, 2020

TB Alliance Announces Partnership with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

Non-profit drug developer partners with leading manufacturer of tuberculosis medicine in China
October 28, 2019

TB Alliance and Macleods Announce Commercial Partnership for New Therapy for Highly Drug-Resistant TB

Non-profit product development partnership and generic manufacturer agree to produce new TB drug for countries with high incidence of TB
October 17, 2019

With One and a Half Million People Dying from TB Every Year, It’s Time to Accelerate Progress

Statement from TB Alliance on WHO Global TB Report 2019
September 23, 2019

TB Alliance Statement on TB REACH Wave 7

A Welcome Investment in TB Treatment
August 14, 2019

FDA Approves New Treatment for Highly Drug-Resistant Forms of Tuberculosis

Pretomanid, developed by the non-profit TB Alliance, has received U.S. approval in combination regimen with bedaquiline and linezolid for people with XDR-TB or treatment-intolerant/non-responsive MDR-TB